What is Veracyte's D&A?

Veracyte (VCYT) reported D&A of $5.43M in Q1 2026.

How has Veracyte's D&A changed year-over-year?

Veracyte's D&A increased by 1.3% year-over-year, from $5.36M to $5.43M.

What is the long-term trend for Veracyte's D&A?

Over 4 years (2021 to 2025), Veracyte's D&A has grown at a 7.6% compound annual growth rate (CAGR), from $15.98M to $21.42M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Veracyte VCYT D&A

D&A at other companies

Labcorp HoldingsLH

$75.6M+8.6%

Quest DiagnosticsDGX

$37M-5.1%

Adaptive BiotechnologiesADPT

$419K0.0%

IQVIAIQV

$288M+8.7%

Natera, Inc.NTRA

——

RevvityRVTY

——

Other financials

Income statement

See full

Revenue$139.1M+21.5%

Gross profit$101.2M+27.2%

Operating income$22.6M+680%

Net income$28.7M+307%

EPS (diluted)$0.35+289%

Balance sheet

See full

Cash & equivalents$264.8M+41.0%

Total debt$39.3M-22.1%

Total equity$1.3B+12.5%

Total assets$1.4B+9.2%

Cash flow

See full

Operating cash flow$35.2M+557%

CapEx$3.0M+62.8%

Free cash flow$32.3M+810%

Valuation

See full

Market cap$4.29B+10.7%

Profitability

See full

Gross margin70.9%+2.9pp

Operating margin14.3%+9.2pp

Net margin16.2%+9.1pp

FCF margin28.7%+11.7pp

Returns & leverage

See full

Return on equity6.9%+4.1pp

Debt / equity0×0.0×

Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Veracyte's D&A?: Veracyte (VCYT) reported D&A of $5.43M in Q1 2026.
How has Veracyte's D&A changed year-over-year?: Veracyte's D&A increased by 1.3% year-over-year, from $5.36M to $5.43M.
What is the long-term trend for Veracyte's D&A?: Over 4 years (2021 to 2025), Veracyte's D&A has grown at a 7.6% compound annual growth rate (CAGR), from $15.98M to $21.42M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.